The 2022 ASH Annual Meeting is due to take place on December 10-13 in New Orleans, Louisiana. Get yourself prepared with Evaluate Vantage's preview of the biggest news expected from the haematology world.

Our roundup includes details on the abstract drops and the market reactions, with expert commentary and analysis. Evaluate Vantage will also be reporting live from the event over the weekend.

Access your copy of the ASH 2022 Preview below.  



Affimed and Aptose score

In oncology settings outside multiple myeloma investors have picked two early winners.

Waiting for Editas

Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
A new multiple myeloma mechanism makes a splash

Talquetamab gets top billing in the press programme, but the data raise important issues about the role of targeting GPRC5D.

Argenx’s expansion plans come into focus

Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.